Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Haemophilia B With Inhibitors Clear all

Conditions: Hemophilia A
Interventions: recombinant porcine coagulation factor VIII (OBI-1); Drug
Lead sponsor: Octagen Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Blue Bell, Pennsylvania

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: vatreptacog alfa (activated), eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 10 more

Conditions: Haemophilia A and B With and Without Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 19
States / cities: San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more

Conditions: Hemophilia
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 2 more

Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 12 Years to 75 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Augusta, Georgia + 9 more

Conditions: Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
Interventions: eptacog alfa (activated), vatreptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Hemophilia A
Interventions: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 75 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Peoria, Illinois • Winston-Salem, North Carolina • Cleveland, Ohio

Conditions: Hemophilia B with Inhibitor, Hemophilia B
Interventions: SerpinPC; Drug
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Tampa, Florida • Greenville, North Carolina

Conditions: Hemophilia A, Hemophilia B
Interventions: MOD-5014; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 7 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
Interventions: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Hemophilia A, Hemophilia B
Interventions: Recombinant Factor VIIa BI (rFVIIa BI); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions: Coagulation FVIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas

Search by objective public record fields.

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

BAX 802 in CHA With Inhibitors

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

PROPACT: Retrospective Prophylaxis Patient Case Collection

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa